- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

Eli Lilly on Sunday launched a DTC campaign for its injectable diabetes drug Trulicity as it seeks to build market share in the competitive GLP-1 receptor agonist class, which has four other approved ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

The labeling for Trulicity (dulaglutide; Eli Lilly) has been updated to include use in combination with basal insulin for adults with type 2 diabetes, following approval from the Food and Drug ...

Trulicity was late to the next-generation diabetes treatment party, so Eli Lilly ($LLY) knew its launch would have to be different. The traditional U.S. strategy ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...

FILE- In this July 11, 2018, file photo, Bridgett Snelten holds her Trulicity injection at her home in Sandy, Utah. Drugmaker Eli Lilly has started posting price information online for drugs ...

Dec 16 (Reuters) - The U.S. health regulator has added Eli Lilly and Co's (LLY.N), opens new tab Mounjaro to its list of drugs facing shortages, highlighting the company's struggles to meet booming ...